Literature DB >> 22388170

Application of external review for subject selection in a schizophrenia trial.

Steven D Targum, Jessica A Little, Enrique Lopez, Nick Demartinis, Mark Rapaport, Larry Ereshefsky.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22388170     DOI： 10.1097/JCP.0b013e318248da90

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  4 in total

1.  A Novel Methodology to Estimate the Treatment Effect in Presence of Highly Variable Placebo Response.

Authors:  Roberto Gomeni; Navin Goyal; Françoise Bressolle; Maurizio Fava
Journal:  Neuropsychopharmacology       Date:  2015-04-21       Impact factor: 7.853

2.  Effects of a novel phosphodiesterase 10A inhibitor in non-human primates: A therapeutic approach for schizophrenia with improved side effect profile.

Authors:  Gunasingh J Masilamoni; Subramanian Uthayathas; Gerhard Koenig; Liza Leventhal; Stella M Papa
Journal:  Neuropharmacology       Date:  2016-08-15       Impact factor: 5.250

Review 3.  Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.

Authors:  George S Baillie; Gonzalo S Tejeda; Michy P Kelly
Journal:  Nat Rev Drug Discov       Date:  2019-08-06       Impact factor: 84.694

4.  A structured interview guide for global impressions: increasing reliability and scoring accuracy for CNS trials.

Authors:  Steven D Targum; Celine Houser; Joanne Northcutt; Jessica A Little; Andrew J Cutler; David P Walling
Journal:  Ann Gen Psychiatry       Date:  2013-01-31       Impact factor: 3.455
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.